Skip to content

Effect of beef consumption on lipid metabolism

Nutrigenomic effect of the consumption of beef in the lipid metabolism of adults clinically healthy from the northeast of Mexico - NUTRIRES

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
RPCEC
Registry ID
RPCEC00000302
Enrollment
32
Registered
2019-08-23
Start date
2019-09-23
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipid metabolism

Interventions

Group A (Experimental): 120 g of beef of specialized sale with a high content of monounsaturated fatty acids (race Wagyu-cross) three days a week for two weeks, prohibited consuming pork, fish or shel
Food
Diet, Food, and Nutrition
Food and Beverages
Fatty Acids, Monounsaturated

Sponsors

Center for Genomic Biotechnology - National Polytechnic Institute (IPN-Reynosa), Mexico
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Patients older than 18 years 2. Aged between18 and 45 years 3. Body mass index (BMI) = 17 kg/m2 and under 45 kg/m2 4. Eat beef 5. Signature written informed consent of the volunteer

Exclusion criteria

Exclusion criteria: 1. Type 1 or type 2 diabetes 2. Hypertension (defined as systolic blood pressure =140 or diastolic blood pressure = 90 mmHg) 3. Chronic diseases (of the hepatic, renal and cardiovascular systems, pancreatitis or some type of malignancy condition) or acute at the time of inclusion 4. Alcoholism and/or drug dependence 5. Smoker (> 10 cigarettes a day) 6. Women who are pregnant or breastfeeding 7. Medicine consumption of or dietary supplements 8. The volunteer no longer wishes to be part of the study 9. Inability to comply with the instructions of the investigation

Design outcomes

Primary

MeasureTime frame
Cholesterol (value in mg/dL). Measurement time: at baseline (time 0) and 2 weeks Triglycerides (value in mg/dL). Measurement time: at baseline (time 0) and 2 weeks HDL-c (value in mg/dL). Measurement time: at baseline (time 0) and 2 weeks LDL-c (value in mg/dL). Measurement time: at baseline (time 0) and 2 weeks VLDL-C (value in mg/dL). Measurement time: at baseline (time 0) and 2 weeks Atherogenic index (Castelli index). Measurement time: at baseline (time 0) and 2 weeks

Secondary

MeasureTime frame
Efficacy outcomes: 1. Measurements and anthropometric indexes. Measurement time: at baseline (time 0) and 2 weeks. It will measure by: -Body Max Index-BMI (Weight/(Height*Height). The weight expressed in Kg and, the height expressed in meters) -Waist circumference (Value expressed in cm). Measurement time: at baseline (time 0) and 2 weeks - Hip circumference (Value expressed in cm) - Waist-hip Index (Waist circumference/Hip circumference. All values are expressed in cm). 2. Glucose on an empty stomach (Value expressed in mg/dL). Measurement time: at baseline (time 0) and 2 weeks. 3. Biochemistry test (BUN, Urea, Creatinine, Uric acid, Total bilirubin, Direct bilirubin, Indirect bilirubin, TGO, TGP, LDH, Alkaline phosphatase, GGT, Total proteins, Albumin, Globulin, Albumin-globulin ratio, Calcium, Phosphorus, CPK, Sodium, Potassium, Chlorine (All are expressed as numerical values in the measurement units of the institution). Measurement time: at baseline (time 0) and 2 weeks

Countries

Mexico

Contacts

Public ContactDiana Vela-Vasquez

Center for Genomic Biotechnology - National Polytechnic Institute

dvelav@alumno.ipn.mx

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Apr 4, 2026